| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Biological relevance of oxytocin and oxytocin receptors in cancer cells and primary tumors
|
Cassoni, P.
|
|
|
12 |
S2 |
p. S37-S39
|
article
|
| 2 |
Chemotherapy and biotherapy in the treatment of neuroendocrine tumours
|
Öberg, K.
|
|
|
12 |
S2 |
p. S111-S114
|
article
|
| 3 |
Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience
|
Stivanello, M.
|
|
|
12 |
S2 |
p. S73-S77
|
article
|
| 4 |
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours
|
Seregni, E.
|
|
|
12 |
S2 |
p. S69-S72
|
article
|
| 5 |
Clinical significance of neuroendocrine carcinoma of the breast
|
Sapino, A.
|
|
|
12 |
S2 |
p. S115-S117
|
article
|
| 6 |
Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer
|
Carnaghi, C.
|
|
|
12 |
S2 |
p. S119-S123
|
article
|
| 7 |
Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy
|
Virgolini, I.
|
|
|
12 |
S2 |
p. S41-S45
|
article
|
| 8 |
Copyright
|
|
|
|
12 |
S2 |
p. iv
|
article
|
| 9 |
Deregulation of genetic pathways in neuroendocrine tumors
|
Calender, A.
|
|
|
12 |
S2 |
p. S3-S11
|
article
|
| 10 |
Ectopic ACTH syndrome: Molecular bases and clinical heterogeneity
|
Terzolo, M.
|
|
|
12 |
S2 |
p. S83-S87
|
article
|
| 11 |
Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: Relevant clinical aspects
|
Doga, M.
|
|
|
12 |
S2 |
p. S89-S94
|
article
|
| 12 |
Editorial board
|
|
|
|
12 |
S2 |
p. v
|
article
|
| 13 |
Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours
|
Tomassetti, P.
|
|
|
12 |
S2 |
p. S95-S99
|
article
|
| 14 |
Expression of neuropeptide Y receptors in human prostate cancer cells
|
Magni, P.
|
|
|
12 |
S2 |
p. S27-S29
|
article
|
| 15 |
Impact of chromogranin A measurement in the work-up of neuroendocrine tumors
|
Baudin, E.
|
|
|
12 |
S2 |
p. S79-S82
|
article
|
| 16 |
Introduction
|
Dogliotti, L.
|
|
|
12 |
S2 |
p. S1-S2
|
article
|
| 17 |
Nerve-driven immunity: Neuropeptides regulate cytokine secretion of T cells and intestinal epithelial cells in a direct, powerful and contextual manner
|
Levite, M.
|
|
|
12 |
S2 |
p. S19-S25
|
article
|
| 18 |
Neuroendocrine aspects of immunolymphoproliferative diseases
|
Ferone, D.
|
|
|
12 |
S2 |
p. S125-S130
|
article
|
| 19 |
Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status
|
Bonkhoff, H.
|
|
|
12 |
S2 |
p. S141-S144
|
article
|
| 20 |
Neuroendocrine differentiation in prostatic carcinoma: An update on recent developments
|
di Sant’Agnese, P.A.
|
|
|
12 |
S2 |
p. S135-S140
|
article
|
| 21 |
Neuroendocrine pathogenesis in adenocarcinoma of the prostate
|
Hansson, J.
|
|
|
12 |
S2 |
p. S145-S152
|
article
|
| 22 |
Neuroendocrine tumors in the brain
|
Cavalla, P.
|
|
|
12 |
S2 |
p. S131-S134
|
article
|
| 23 |
Nuclear medicine imaging of neuroendocrine tumours
|
Bombardieri, E.
|
|
|
12 |
S2 |
p. S51-S61
|
article
|
| 24 |
Oncogenes, growth factors, receptor expression and proliferation markers in digestive neuroendocrine tumours. A critical reappraisal
|
Delle Fave, G.
|
|
|
12 |
S2 |
p. S13-S17
|
article
|
| 25 |
Potential clinical value of circulating chromogranin A in patients with prostate carcinoma
|
Berruti, A.
|
|
|
12 |
S2 |
p. S153-S157
|
article
|
| 26 |
Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma
|
Bollito, E.
|
|
|
12 |
S2 |
p. S159-S164
|
article
|
| 27 |
Somatostatin receptor subtype expression in human tumors
|
Hofland, L.J.
|
|
|
12 |
S2 |
p. S31-S36
|
article
|
| 28 |
Surgical strategy in the treatment of gastrointestinal neuroendocrine tumours
|
Falconi, M.
|
|
|
12 |
S2 |
p. S101-S103
|
article
|
| 29 |
Table of Contents
|
|
|
|
12 |
S2 |
p. iii
|
article
|
| 30 |
The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: Comparison with standard subcutaneous octreotide therapy
|
Dogliotti, L.
|
|
|
12 |
S2 |
p. S105-S109
|
article
|
| 31 |
The gut as the largest endocrine organ in the body
|
Ahlman, H.
|
|
|
12 |
S2 |
p. S63-S68
|
article
|
| 32 |
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours
|
Kaltsas, G.A.
|
|
|
12 |
S2 |
p. S47-S50
|
article
|
| 33 |
Title Page
|
|
|
|
12 |
S2 |
p. ii
|
article
|
Journal description